Sentence: It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with bevacizumab + capecitabine + oxaliplatin ( XELOX ) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer ( mCRC ) .
Drug combination annotation:
[{'class': 'POS', 'spans': ['bevacizumab', 'capecitabine'], 'is_context_needed': True}, {'class': 'COMB', 'spans': [2, 3, 4], 'is_context_needed': True}]